Will a study suggest GLP-1 agonists (and similar) have an effect on bulimia nervosa frequency or work as a treatment?
1
Ṁ100Ṁ102029
1H
6H
1D
1W
1M
ALL
50%
Yes, possible preventative/treatment effect
50%
Yes, possible deleterious effect
63%
No, no paper or one with an unclear finding
I'm looking for preprints or journal-published papers that are, to my estimation, reasonably credible. Any medical professionals, researchers, or watchdogs are free to weigh in with "seems reasonable" or "seems sus."
I'm not looking for solid, hard proof; just something interesting or suggestive.
Papers should have numbers and some reasonable statistical analyses, not just speculation.
Anecdotes won't be considered. Documents that aren't preprints or journal-published papers might be enough to resolve the market if they seem similarly practically credible, especially if e.g. there are examples of doctors who are also science communicators (e.g. Science-Based Medicine) treating them as credibly interesting.
This question is managed and resolved by Manifold.
Market context
Get
1,000 to start trading!
People are also trading
Related questions
Will there be medical consensus that GLP-1 drugs have cardiovascular benefits beyond those provided via weight loss?
71% chance
By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?
86% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
86% chance
Will a junk/fast food company use engineered additives to mitigate the effects of GLP-1 agonists (Ozempic)?
14% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will Donald Trump ever take a GLP-1 agonist (eg Ozempic, Mounjaro, Wegovy, Zepbound, etc) for weight loss
55% chance
Before 2033, will semaglutide be shown to improve lifespan, when prescribed to overweight people?
83% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
10% chance
Clinical trial shows by 2030 that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms
68% chance
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...